Barclays PLC Alx Oncology Holdings Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Barclays PLC holds 59,502 shares of ALXO stock, worth $96,393. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,502

Previous 59,502 -0.0%

Holding current value

$96,393

Previous $107,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$1.81 - $8.13 $76,354 - $342,964	42,185 Added 243.6%	59,502 $107,000
Q2 2024 Aug 14, 2024	SELL	$5.84 - $17.56 $66,097 - $198,744	-11,318 Reduced 39.53%	17,317 $105,000
Q1 2024 May 15, 2024	SELL	$10.95 - $16.79 $175,221 - $268,673	-16,002 Reduced 35.85%	28,635 $319,000
Q4 2023 Feb 15, 2024	BUY	$4.81 - $15.38 $85,007 - $271,810	17,673 Added 65.54%	44,637 $664,000
Q3 2023 Nov 07, 2023	BUY	$4.19 - $7.35 $41,045 - $72,000	9,796 Added 57.06%	26,964 $129,000
Q2 2023 Aug 03, 2023	BUY	$4.37 - $9.56 $7,083 - $15,496	1,621 Added 10.43%	17,168 $130,000
Q1 2023 May 04, 2023	BUY	$4.52 - $11.71 $18,165 - $47,062	4,019 Added 34.86%	15,547 $70,000
Q4 2022 Feb 13, 2023	BUY	$9.51 - $12.95 $46,133 - $62,820	4,851 Added 72.65%	11,528 $130,000
Q3 2022 Nov 03, 2022	BUY	$8.23 - $15.14 $20,278 - $37,304	2,464 Added 58.49%	6,677 $64,000
Q2 2022 Aug 12, 2022	SELL	$5.89 - $19.46 $2,909 - $9,613	-494 Reduced 10.5%	4,213 $34,000
Q1 2022 May 16, 2022	BUY	$13.65 - $22.06 $64,250 - $103,836	4,707 New	4,707 $80,000

Others Institutions Holding ALXO

# of Institutions

101

Shares Held

39.7M

Call Options Held

134K

Put Options Held

17.4K

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $66M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account